Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Oral cyclosporine A treatment is feasible after myeloablative conditioning in allogeneic hematopoietic stem cell transplantation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Dosage dependent hormonal counter regulation to combination therapy in patients with left ventricular dysfunction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Insulin-Like Growth Factor Gene Polymorphisms Predict Clinical Course in Allogeneic Hematopoietic Stem Cell Transplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. "Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation"

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

WHAT IS KNOWN AND OBJECTIVE: The target level and route of administration of cyclosporine A (CsA) differ between transplantation centres. It is unclear whether oral CsA is sufficient to maintain target level of CsA.

CASE SUMMARY: We retrospectively analysed data from 48 adult patients, who underwent myeloablative hematopoietic stem cell transplantation. Twenty-one patients (44%) tolerated CsA orally throughout the transplantation period without increased incidence of acute graft versus host disease(aGVHD). Low concentration of CsA in week 2 was associated with increased incidence of aGVHD.

WHAT IS NEW AND CONCLUSION: Oral administration of CsA is safe, less time-consuming and economically advantageous. Close monitoring of CsA concentration is important.

OriginalsprogEngelsk
TidsskriftJournal of Clinical Pharmacy and Therapeutics
Vol/bind40
Udgave nummer3
Sider (fra-til)358-61
Antal sider4
ISSN0269-4727
DOI
StatusUdgivet - jun. 2015

ID: 46003710